Invasive pulmonary artery pressure monitoring in heart failure: evidence, clinical application, and future directions

Hemodynamic congestion frequently precedes overt deterioration in heart failure (HF), offering an opportunity for earlier intervention through remote invasive monitoring. Among available systems, pulmonary artery pressure (PAP)-guided management with CardioMEMS has the most mature randomized evidence for reducing recurrent HF hospitalizations and improving health status, although a consistent survival benefit across the HF spectrum has not been established. Clinical implementation requires individualized pressure targets, sustained trend interpretation, regular patient transmissions, and prompt therapeutic responses. The most directly actionable interventions are adjustments to decongestive treatment; prognostic HF therapies should be prescribed and maintained according to guideline indications rather than PAP readings alone. Persistent worsening-HF events warrant reassessment of signal quality, therapeutic response, and alternative mechanisms of deterioration. Device longevity must be distinguished from long-term calibration accuracy, while post-marketing safety data require cautious interpretation. The incremental benefit of pressure monitoring in patients receiving fully contemporary pharmacological treatment remains uncertain. Emerging pulmonary artery, left atrial, and inferior vena cava platforms have different physiological targets, monitoring workflows, and levels of clinical evidence. This narrative review critically appraises the physiological rationale, randomized and real-world evidence, clinical management, device performance, safety, and future development of implantable hemodynamic monitoring in HF.